Dirk Sibbing/LinkedIn
Nov 17, 2025, 05:31
Dirk Sibbing: New Data Strengthen the Case for Prasugrel in ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Following ISAR-REACT 5 and the recently published large Danisch registry in > 10,000 pts more data is accumulating that benefits praugrel over ticagrelor for PCI in ACS patients.
See the interesting coverage and analysis with comments from Sripal Bangalore and Ajay Kirtane on TCTMD on TUXEDO-2, a randomized comparison that focused on diabetic patients with multivessel disease undergoing PCI.”
Find more information here.
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
-
Aug 23, 2026, 16:03Balaji Balagani: Major Causes of Sudden Cardiac Death in Children
-
Aug 23, 2026, 16:02Bartosz Hudzik: What’s Hot at ESC Congress 2026